ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.098,09
-0,50%
S&P 500
5.277,51
0,80%
US Dollar vs BRL
5,2459
0,00%
Bitcoin
67.607,87
0,19%
Brent Oil
81,295
0,00%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Structure Therapeutics Inc (GPCR)

  7. Structure Therapeutics Inc (GPCR) Notícias

GPCR

Structure Therapeutics (GPCR)

Structure Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:GPCR
DataHoraFonteTítuloCódigoCompanhia
09/05/202417:56Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GPCRStructure Therapeutics Inc
09/05/202417:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GPCRStructure Therapeutics Inc
09/05/202417:05GlobeNewswire Inc.Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent HighlightsNASDAQ:GPCRStructure Therapeutics Inc
08/03/202418:19Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:GPCRStructure Therapeutics Inc
08/03/202418:05GlobeNewswire Inc.Structure Therapeutics to Present at Leerink Partners Global Biopharma ConferenceNASDAQ:GPCRStructure Therapeutics Inc
08/03/202411:19Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:GPCRStructure Therapeutics Inc
08/03/202410:30GlobeNewswire Inc.Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent HighlightsNASDAQ:GPCRStructure Therapeutics Inc
18/12/202309:30GlobeNewswire Inc.Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical StudyNASDAQ:GPCRStructure Therapeutics Inc
30/11/202302:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:GPCRStructure Therapeutics Inc
17/11/202319:25Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:GPCRStructure Therapeutics Inc
17/11/202318:51Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:GPCRStructure Therapeutics Inc
14/11/202318:10GlobeNewswire Inc.Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent HighlightsNASDAQ:GPCRStructure Therapeutics Inc
29/09/202308:32GlobeNewswire Inc.Structure Therapeutics Announces $300 Million Private Placement Equity FinancingNASDAQ:GPCRStructure Therapeutics Inc
29/09/202308:30GlobeNewswire Inc.Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program UpdateNASDAQ:GPCRStructure Therapeutics Inc
10/08/202317:05GlobeNewswire Inc.Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent HighlightsNASDAQ:GPCRStructure Therapeutics Inc
03/08/202318:32GlobeNewswire Inc.Structure Therapeutics Appoints Ted W. Love, M.D., to Board of DirectorsNASDAQ:GPCRStructure Therapeutics Inc
07/06/202309:30GlobeNewswire Inc.Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific SessionsNASDAQ:GPCRStructure Therapeutics Inc
05/06/202317:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:GPCRStructure Therapeutics Inc
31/05/202317:30GlobeNewswire Inc.Structure Therapeutics to Present at Jefferies Healthcare ConferenceNASDAQ:GPCRStructure Therapeutics Inc
25/05/202317:30GlobeNewswire Inc.Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and ObesityNASDAQ:GPCRStructure Therapeutics Inc
18/05/202317:30GlobeNewswire Inc.Structure Therapeutics Announces Poster Presentations at the American Thoracic Society International ConferenceNASDAQ:GPCRStructure Therapeutics Inc
11/05/202318:01Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:GPCRStructure Therapeutics Inc
11/05/202317:30GlobeNewswire Inc.Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent HighlightsNASDAQ:GPCRStructure Therapeutics Inc
30/03/202318:16Edgar (US Regulatory)Annual Report (10-k)NASDAQ:GPCRStructure Therapeutics Inc
30/03/202317:30GlobeNewswire Inc.Structure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent HighlightsNASDAQ:GPCRStructure Therapeutics Inc
13/02/202319:29Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:GPCRStructure Therapeutics Inc
07/02/202318:00GlobeNewswire Inc.Structure Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary SharesNASDAQ:GPCRStructure Therapeutics Inc
04/02/202302:15PR Newswire (US)Qiming Venture Partners Backed Structure Therapeutics Successfully Debuts on NasdaqNASDAQ:GPCRStructure Therapeutics Inc
02/02/202321:41GlobeNewswire Inc.Structure Therapeutics Announces Pricing of Upsized Initial Public OfferingNASDAQ:GPCRStructure Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:GPCR

Seu Histórico Recente

LSE
HB83
Citi Fun 24
TSX
ZESG
BMO Balanced ESG ETF
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados